

Test Report: BS EN 14476:2013 + A2:2019 Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of virucidal activity in the medical area- Test method and requirements (Phase 2/Step 1)

Test Laboratory**BluTest Laboratories Ltd**

5 Robroyston Oval, Nova Business Park, Glasgow G33 1AP

Identification of sample

Name of the product	Velox Oxy ETA
Batch number	181220_96
Client	Medisept Sp. Z.o.o
Client address	Konopnica 159C, 21-030 Konopnica
Project code	BT-MDS-02
Date of delivery	29 January 2021
Storage conditions	Ambient
Active substances	Not indicated
Appearance	Liquid
Condition upon receipt	Undamaged

Test Method and Neutralisation

Method	1 part interfering substance + 1 part virus suspension + 8 parts biocide were mixed and incubated at the indicated contact temperature for the indicated contact times. Assays were validated by a cytotoxicity control, interference control, neutralization control and a formaldehyde internal standard.
Neutraliser	Dilution-neutralization/gel filtration/ enhanced neutralisation on highest dilution; Dulbecco's modified Eagles medium + 5% v/v foetal bovine serum at 4°C

Experimental Conditions

Period of analysis	15 April 2021 to 28 April 2021
Product diluent used	Sterile distilled water
Product test concentrations	60.0% v/v; 70.0% v/v; 80.0% v/v (poliovirus only) 1.0% v/v; 10.0% v/v; 25.0% v/v; 50.0% v/v (adenovirus only)
Appearance product dilutions	No changes noted- stable
Appearance in test mixture	Turbidity and sedimentation observed at 70.0% v/v; 80.0% v/v (poliovirus only)
Contact time	t = 15 seconds; 30 seconds; 1 mins ± 5 s
Test temperature	20°C ± 1°C
Interfering substance	3.0g/l bovine albumin + 3.0g/l sheep erythrocytes
Temperature of incubation	37°C ± 1°C + 5% CO2

Test Organism(s)

Identification and passage (P) of virus	Adenovirus-5 ATCC VR-5 (P 08) Poliovirus-1 LSc-2ab (NIBSC Code 01/528) (P 07)
---	--

Identification and passage (P) of cells

HeLa cells (*Poliovirus type 1*) (P 34)HeLa cells (*Adenovirus type 5*) (P 35)

PROTOCOL SUMMARY

The basic virucidal efficacy test is set up with three/four concentrations of test product solution and a 15 second, 30 second- and 1-minute contact time. Virus is exposed to disinfectant in 24-well plates, then neutralised, serially diluted and virus titred in 96-well tissue culture plates to determine the tissue culture infectious dose₅₀ (TCID₅₀) of surviving virus. *Poliovirus type 1* (LSc-2ab/NIBSC Code 01/528)/HeLa cells and *Adenovirus type 5* (ATCC VR-5)/HeLa cells are assayed in parallel in each test. TCID₅₀ is determined by the method of Karber¹.

Cytotoxicity control

The test product solution is measured for its effects on the host cells used to propagate the virus, to determine the sensitivity of the assay.

Interference control

The effect of the cells after treatment of the test product solution are verified to ensure the cells can show susceptibility for virus infection. This is compared against cells that have not been treated with test product.

Disinfectant suppression control VS1

Virus is added to the highest concentration of test product solution and then the mixture immediately removed and neutralised. The neutralised virus titre is then determined to assess the efficiency of the neutralisation procedure.

Disinfectant suppression control VS2

Internal control which adds virus to neutralised test product solution to assess the efficiency of the neutralisation procedure.

No column Control

Internal control on the highest contact time to assess any impact of the Microspin™ S 400 HR columns.

Virus recovery control

Virus titre is determined for virus in contact with sterile hard water/ sterile, synthetic hard water at t=0, t = 1 and at t =60. The virus titre after 1 minute is then compared to the recovery of disinfectant-treated virus to measure the log reduction in virus titre. The virus titre at 60 minutes is compared to the reference virus inactivation control.

Reference virus inactivation control

Virus is exposed to 0.7% W/V formaldehyde and the recovery of virus determined by TCID₅₀ after 30 and 60 minutes, in order to assess that the test virus has retained reproducible biocide resistance. In addition, the formaldehyde cytotoxicity of neutralised formaldehyde is determined, to measure assay sensitivity.

1Kärber, G.: Beitrag zur Kollektiven Behandlung Pharmakologischer Reihenversuche. Arch. Exp. Path. Pharmak. 162 (1931): 480-483.

Adenovirus type 5 (ATCC VR-5) Test Results

EN14476:2013 + A2:2019 Suspension test for the efficacy of Velox Oxy ETA, Batch 181220_96, BT-MDS-02 from Medisept Sp. Z.o.o against Adenovirus-5 ATCC VR-5 under DIRTY conditions

Test Results								
Concentration	1.0% (v/v)		10.0% (v/v)		25.0% (v/v)		50.0% (v/v)	
Exposure Time	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml
t = 15 seconds	4.67	1.47E+06	2.67	1.47E+04	2.33	6.81E+03	1.17	4.64E+02
Raw Data	666640	1.47E+06	663100	1.47E+04	662000	6.81E+03	610000	4.64E+02
log		6.17		4.17		3.83		2.67
log difference		0.33		2.33		2.67		3.83
t = 30 seconds	3.83	2.15E+05	3.00	3.16E+04	2.33	6.81E+03	1.00	3.16E+02
Raw Data	666500	2.15E+05	666000	3.16E+04	662000	6.81E+03	600000	3.16E+02
log		5.33		4.50		3.83		2.50
log difference		1.17		2.00		2.67		4.00
t = 1 minute	3.83	2.15E+05	2.50	1.00E+04	2.17	4.64E+03	1.00	3.16E+02
Raw Data	666500	2.15E+05	663000	1.00E+04	661000	4.64E+03	600000	3.16E+02
log		5.33		4.00		3.67		2.50
log difference		1.17		2.50		2.83		4.00

Adenovirus type 5 (ATCC VR-5) Control Data

Adenovirus-5 ATCC VR-5 Controls											
Virus Recovery 0 min		Virus Recovery 1 min		Virus Recovery 60 min		Cytotoxicity		Disinfectant Suppression VS		Disinfectant Suppression VS2	
raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml
5.00	3.16E+06	5.00	3.16E+06	5.00	3.16E+06	1.00	3.16E+02	1.50	1.00E+03	5.33	6.81E+06
666660	3.16E+06	666660	3.16E+06	666660	3.16E+06	600000	3.16E+02	630000	1.00E+03	666662	6.81E+06
	6.50		6.50		6.50		2.50		3.00		6.83
									3.50		-0.33
Formaldehyde reference inactivation controls								No column Control			
Cytotoxicity		Exposure time	0.7% Formaldehyde				raw data		TCID ₅₀ /ml		
			30 mins		60 mins						
raw data	TCID ₅₀ /ml		raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml					
1.00	3.16E+02		1.00	3.16E+02	1.00	3.16E+02			5.33		
600000	3.16E+02		600000	3.16E+02	600000	3.16E+02			666662		
	2.50	log		2.50		2.50			6.83		
		log difference		4.00		4.00					
Interference control		Virus dilution						Stock Virus (TCID ₅₀)			
		-3	-4	-5	-6	-7	-8	6.50			
PBS Control		1	1	1	1	0.33	0.17	1.00E+08			
		3.16E+02	3.16E+02	3.16E+02	3.16E+02	6.76E+01	4.68E+01	666663			
		2.50	2.50	2.50	2.50	1.83	1.67				
Raw Data		6	6	6	6	2	1				
Product		1	1	1	1	0.33	0				
		3.16E+02	3.16E+02	3.16E+02	3.16E+02	6.76E+01	3.16E+01				
		2.50	2.50	2.50	2.50	1.83	1.50				
Raw Data		6	6	6	6	2	0				
Log Difference		0.00	0.00	0.00	0.00	0.00	0.17				
Product Cyt Dilution		-2	-2	-2	-2	-2	-2				
PBS Dilution		Neat	Neat	Neat	Neat	Neat	Neat				

Adenovirus type 5 (ATCC VR-5) Summary Table

Adenovirus-5 ATCC VR-5 Summary Table									
Product:	Interfering substance	Concentration	Level of cytotoxicity	lg TCID ₅₀					>4 lg reduction after 'X' Min
				0 min	15 secs	30 secs	1 min	60 min	
Velox Oxy ETA	3.0g/l BSA + 3.0ml/l erythrocytes	50.0% (v/v)	2.50	3.00	2.67	2.50	2.50	n.a.	30 secs
		25.0% (v/v)	2.50	n.a.	3.83	3.83	3.67	n.a.	>1 min
		10.0% (v/v)	2.50	n.a.	4.17	4.50	4.00	n.a.	>1 min
		1.0% (v/v)	2.50	n.a.	6.17	5.33	5.33	n.a.	>1 min
Velox Oxy ETA	3.0g/l BSA	50.0% (v/v)	2.50	n.a.	2.67	2.50	2.50	n.a.	15 secs
		25.0% (v/v)	2.50	n.a.	4.00	3.83	3.50	n.a.	>1 min
		10.0% (v/v)	2.50	n.a.	6.00	6.00	5.50	n.a.	>1 min
		1.0% (v/v)	2.50	n.a.	6.33	5.50	5.50	n.a.	>1 min
Virus Control	DIRTY			6.50	n.a.	n.a.	6.50	6.50	n.a.
Virus Control	3.0g/l BSA			6.50	n.a.	n.a.	6.50	6.67	n.a.
							30 min	60 min	
Formaldehyde	PBS	0.7% (w/v)	2.50				2.50	2.50	>60 mins

Adenovirus type 5 (ATCC VR-5) Control Data

Adenovirus-5 ATCC VR-5 Parallel Control Test														
Controls						Test Results								
Virus Recovery 0 min		Virus Recovery 1 min		Virus Recovery 60 min		Concentration	1.0% (v/v)		10.0% (v/v)		25.0% (v/v)		50.0% (v/v)	
raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	Exposure Time	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml
5.00	3.16E+06	5.00	3.16E+06	5.17	4.64E+06	t = 15 seconds	4.83	2.15E+06	4.50	1.00E+06	2.50	1.00E+04	1.17	4.64E+02
666651	3.16E+06	666660	3.16E+06	666652	4.64E+06	Raw data	666641	2.15E+06	666630	1.00E+06	663000	1.00E+04	610000	4.64E+02
	6.50		6.50		6.67	log		6.33		6.00		4.00		2.67
						log difference		0.17		0.50		2.50		4.00
						Exposure Time	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml
						t = 30 seconds	4.00	3.16E+05	4.50	1.00E+06	2.33	6.81E+03	1.00	3.16E+02
						Raw data	666600	3.16E+05	666630	1.00E+06	662000	6.81E+03	600000	3.16E+02
						log		5.50		6.00		3.83		2.50
						log difference		1.00		0.50		2.67		4.17
						Exposure Time	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml
						t = 1 minute	4.00	3.16E+05	4.00	3.16E+05	2.00	3.16E+03	1.00	3.16E+02
						Raw data	666600	3.16E+05	666600	3.16E+05	660000	3.16E+03	600000	3.16E+02
						log		5.50		5.50		3.50		2.50
						log difference		1.00		1.00		3.00		4.17

Poliovirus type 1 (LSc-2ab/NIBSC Code 01/528) Test Results

EN14476:2013 + A2:2019 Suspension test for the efficacy of Velox Oxy ETA, Batch 181220_96, BT-MDS-02 from Medisept Sp. Z.o.o against Poliovirus type 1 LSc-2ab (NIBSC Code 01/528) under DIRTY conditions

Test Results						
Concentration	60.0% (v/v)		70.0% (v/v)		80.0% (v/v)	
Exposure Time	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml
t = 15 seconds	3.00	3.16E+04	2.00	3.16E+03	1.00	3.16E+02
Raw Data	666000	3.16E+04	660000	3.16E+03	600000	3.16E+02
log		4.50		3.50		2.50
log difference		2.50		3.50		4.50
Exposure Time	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml
t = 30 seconds	2.33	6.81E+03	2.67	1.47E+04	1.00	3.16E+02
Raw Data	661100	6.81E+03	664000	1.47E+04	600000	3.16E+02
log		3.83		4.17		2.50
log difference		3.17		2.83		4.50
Exposure Time	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml
t = 1 minute	2.00	3.16E+03	3.00	3.16E+04	1.00	3.16E+02
Raw Data	660000	3.16E+03	666000	3.16E+04	600000	3.16E+02
log		3.50		4.50		2.50
log difference		3.50		2.50		4.50

Poliovirus type 1 (LSc-2ab/NIBSC Code 01/528) Control Data

Poliovirus type 1 LSc-2ab (NIBSC Code 01/528) Controls											
Virus Recovery 0 min		Virus Recovery 1 min		Virus Recovery 60 min		Cytotoxicity		Disinfectant Suppression VS		Disinfectant Suppression VS2	
raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml
5.50	1.00E+07	5.50	1.00E+07	5.50	1.00E+07	0.00	3.16E+01	3.17	4.64E+04	5.83	2.15E+07
666663	1.00E+07	666663	1.00E+07	666663	1.00E+07	000000	3.16E+01	666100	4.64E+04	666665	2.15E+07
	7.00		7.00		7.00		1.50		4.67		7.33
									2.33		-0.33
Formaldehyde reference inactivation controls								No column Control			
Cytotoxicity		Exposure time	0.7% Formaldehyde				raw data		TCID ₅₀ /ml		
			30 mins		60 mins						
raw data	TCID ₅₀ /ml		raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml					
1.00	3.16E+02		3.50	1.00E+05	2.83	2.15E+04			6.00		
600000	3.16E+02		666300	1.00E+05	665000	2.15E+04			666666		
	2.50	log		5.00		4.33			7.50		
		log difference		2.00		2.67					
Interference control		Virus dilution						Stock Virus (TCID ₅₀)			
		-3	-4	-5	-6	-7	-8				
PBS Control		1	1	1	1	0.67	0.17	7.17			
Raw Data		3.16E+02	3.16E+02	3.16E+02	3.16E+02	1.48E+02	4.68E+01	4.68E+08			
Product		2.50	2.50	2.50	2.50	2.17	1.67	6666666100			
Raw Data		6	6	6	6	4	1				
Log Difference		1	1	1	1	0.83	0				
Product Cyt Dilution		3.16E+02	3.16E+02	3.16E+02	3.16E+02	2.14E+02	3.16E+01				
PBS Dilution		2.50	2.50	2.50	2.50	2.33	1.50				
		6	6	6	6	5	0				
		0.00	0.00	0.00	0.00	-0.16	0.17				
		-1	-1	-1	-1	-1	-1				
		Neat	Neat	Neat	Neat	Neat	Neat				

Poliovirus type 1 (LSc-2ab/NIBSC Code 01/528) Summary table

Poliovirus type 1 LSc-2ab (NIBSC Code 01/528) Summary Table									
Product:	Interfering substance	Concentration	Level of cytotoxicity	lg TCID ₅₀					>4 lg reduction after 'X' Min
				0 min	15 sec	30 sec	1 min	60 min	
Velox Oxy ETA	3.0g/l BSA + 3.0ml/l erythrocytes	80.0% (v/v)	1.50	4.67	2.50	2.50	2.50	n.a.	<15 sec
		70.0% (v/v)	1.50	n.a.	3.50	4.17	4.50	n.a.	>1 min
		60.0% (v/v)	1.50	n.a.	4.50	3.83	3.50	n.a.	>1 min
Velox Oxy ETA	3.0g/l BSA	80.0% (v/v)	1.50	n.a.	4.50	2.50	2.50	n.a.	<30 sec
		70.0% (v/v)	1.50	n.a.	5.00	3.50	4.50	n.a.	>1 min
		60.0% (v/v)	1.50	n.a.	5.00	3.50	4.50	n.a.	>1 min
Virus Control	DIRTY			7.00	n.a.	n.a.	7.00	7.00	n.a.
Virus Control	3.0g/l BSA			7.17	n.a.	n.a.	7.00	7.17	n.a.
							30 min	60 min	
Formaldehyde	PBS	0.7% (w/v)	2.50				5.00	4.33	>60 mins

Poliovirus type 1 (LSc-2ab/NIBSC Code 01/528) Control Data

Poliovirus type 1 LSc-2ab (NIBSC Code 01/528) Parallel Control Test												
Controls						Test Results						
Virus Recovery 0 min		Virus Recovery 1 min		Virus Recovery 60 min		Concentration	60.0% (v/v)		70.0% (v/v)		80.0% (v/v)	
raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	Exposure Time	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml
5.67	1.47E+07	5.50	1.00E+07	5.67	1.47E+07	t = 15 seconds	3.50	1.00E+05	3.50	1.00E+05	3.00	3.16E+04
666664	1.47E+07	666663	1.00E+07	666664	1.47E+07	Raw Data	666300	1.00E+05	666210	1.00E+05	666000	3.16E+04
	7.17		7.00		7.17	log		5.00		5.00		4.50
						log difference		2.00		2.00		2.50
						Exposure Time	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml
						t = 30 seconds	2.00	3.16E+03	2.00	3.16E+03	1.00	3.16E+02
						Raw Data	660000	3.16E+03	660000	3.16E+03	600000	3.16E+02
						log		3.50		3.50		2.50
						log difference		3.50		3.50		4.50
						Exposure Time	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml	data	TCID ₅₀ /ml
						t = 1 minute	3.00	3.16E+04	3.00	3.16E+04	1.00	3.16E+02
						Raw Data	666000	3.16E+04	666000	3.16E+04	600000	3.16E+02
						log		4.50		4.50		2.50
						log difference		2.50		2.50		4.50

CONCLUSION

Verification of the methodology

A test is only valid if the following criteria are fulfilled:

- a) The titre of the test suspension of at least 10^8 TCID₅₀ /ml is sufficiently high to at least enable a titre reduction of 4 lg to verify the method.
- b) Detectable titre reduction is at least 4 log₁₀.
- c) Difference of the logarithmic titre of the virus control minus the logarithmic titre of the test virus in the reference inactivation test is between:
 - Between 0.5 and 2.5 after 30 min and between 2.0 and 4.5 after 60 min for poliovirus
 - Between 3.0 and 5.0 after 30 min and between 3.5 and 5.5 after 60 min for adenovirus
 - Between 1.0 and 3.0 after 30 min and between 2.0 and 4.0 after 60 min for murine norovirus
 - Between 0.0 and 2.0 after 30 min and between 0.5 and 2.5 after 60 min for parvovirus
 - Between 0.75 and 3.5 after 5 min and between 2.0 and 4.0 after 15 min for Vaccinia virus
- d) Cytotoxicity of the product solution does not affect cell morphology and growth or susceptibility for the test virus in the dilutions of the test mixtures which are necessary to demonstrate a 4 log₁₀ reduction of the virus.
- e) The interference control result does not show a difference of > 1.0 log₁₀ of virus titre for test product treated cells in comparison to the non-treated cells.
- f) Neutralisation validation. This is called the disinfectant suppression test in this protocol. The disinfectant was neutralised by column chromatography through an Illustra Microspin S-400 HR column to achieve the best possible neutralisation available for this test. The difference for virus is greater than 0.5 log₁₀ indicating rapid irreversible virucidal activity of the disinfectant by dilution at a concentration of 80.0% v/v/ 50.0% v/v for VS1. This neutralisation validation has been verified by VS2, which shows the product has been successfully neutralised.

According to EN 14476:2013 + A2:2019, **Velox Oxy ETA POSSESSES VIRUCIDAL** activity at a concentration of **50.0% v/v** of the working concentration as tested after **30 SECONDS** at **20°C** under **DIRTY** conditions (3.0 g/l bovine albumin + 3.0 ml/l erythrocytes) against *Adenovirus type 5* (ATCC VR-5)/HeLa cells.

According to EN 14476:2013 + A2:2019, **Velox Oxy ETA POSSESSES VIRUCIDAL** activity at a concentration of **80.0% v/v** of the working concentration as tested after **15 SECONDS** at **20°C** under **DIRTY** conditions (3.0 g/l bovine albumin + 3.0 ml/l erythrocytes) against *Poliovirus type 1* (LSc-2ab/NIBSC Code 01/528)/HeLa cells.

Authorised signatory



Dr Chris Woodall, Director
BluTest Laboratories Ltd
Glasgow, UK
Date: 05 MAY 2021



4597

Expanded Uncertainty of Measurement $U = \pm 0.055$

DISCLAIMER

The results in this test report only pertain to the sample supplied.

BluTest (BT) has performed the testing detailed in this report using reasonable skill and care and has used reasonable endeavours to carry out the testing in accordance with an EN 14476 protocol. All forecasts, recommendations and results contained in this report are submitted in good faith. However, other than as expressly set out in this report, no warranty is given (i) in relation to the testing or the use(s) to which any results or deliverables produced in the course of the testing are or may be put by the Client or their fitness or suitability for any particular purpose or under any special conditions notwithstanding that any such purpose or conditions may have been made known to BT or (ii) that the intended results or deliverables from the testing can be achieved or (iii) that the Client can freely make use of the results or the deliverables without infringing any third party intellectual property rights and the Client will be deemed to have satisfied itself in this regard. BT shall have no liability (which is hereby excluded to the fullest extent permissible by law) in respect of any loss, liability or damage, including without limitation any indirect and/or consequential loss such as loss of profit or loss of business, market or goodwill, that the Client may suffer directly or indirectly as a result of or in connection with: (i) the performance of the testing; (ii) the use of any materials, samples or other information provided by the Client for use in the testing; and (iii) the Client's reliance upon or use of any results or deliverables provided as part of the testing.

This report must not be modified or abbreviated without the permission of the issuing laboratory.